Navigation Links
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Date:6/19/2009

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

"We are disappointed that this study with lestaurtinib did not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for life-threatening diseases," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon.

The results of this study in relapsed AML will be submitted for presentation at a future medical meeting. The outcome of this study has no impact on the company's previously issued financial guidance for 2009.

"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like Cephalon to make that investment and take that risk if we are to improve patient outcomes and the overall cost of healthcare."

Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
2. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
3. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
9. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
10. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
11. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/10/2014)... 2014 Parker Waichman LLP, a ... of victims injured by defective medical devices, reports ... allegations that the woman’s hidden, aggressive leiomyosarcoma was ... used during a routine laparoscopic supracervical hysterectomy procedure. ... Medical Instruments Corporation over its Wolf Power Morcellator ...
(Date:7/10/2014)... record becomes widespread across the United States, due in ... the quantity of clinical data that will become available ... Additionally, experts in healthcare have become increasingly focused ... for the purpose of gleaning insights that have the ... a process that is known as big data. ...
(Date:7/10/2014)... with dyslexia are more likely to report that they ... who don,t have the learning disorder, according to a ... 10 percent of people, causes problems with reading and ... this condition said they suffered physical abuse during their ... "Even after accounting for age, race, sex and ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Men who have ... prostate cancer, a new study suggests. But the ... urologists not involved with the study said more research ... truly accurate. For the study, Harvard researchers analyzed ... followed for 24 years, starting in 1986. During that ...
(Date:7/10/2014)... 10, 2014In response to today,s announcement that the "Mississippi ... has now been found to have detectable levels of ... expresses disappointment in this setback but remains hopeful that ... to remain undetectable for more than two years will ... and ultimately develop a cure. , "Although we ...
Breaking Medicine News(10 mins):Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... donations is spiraling for older couples wanting to start ... ... shifts in parenting,trends have fertility experts at Reproductive Endocrinology Associates of,Charlotte (REACH) ... 2008 -- including new outreach through the Internet --,in efforts to stem ...
... Patent Expands Geographic Coverage, IRVING, ... (OTC Bulletin Board: CARN) today announced ... patent application No. 200600484, titled,"Delivery of ... Anionic,Polysaccharides," relating to the Company,s proprietary ...
... Professor of Epidemiology and Associate Dean for Health Promotion ... of Medicine, and Virginia A. Stallings, MD, PhD, the ... Penn and Professor of Pediatrics at The Childrens Hospital ... a special public session, Understanding Obesity and Childhood at ...
... Nationally in, March 2008 Tells the Story of Six ... Mountain in the Himalayas with Blind Climber ... Entertainment and Junior,Blind of America announced today that from ... (opening March,2008) will travel to the United States for ...
... the Way to Educating Children With Food,Allergies, FAIRFAX, ... (FAAN) is proud to announce the release of two ... allergies.,Alexander, the Elephant Who Couldn,t Eat Peanuts ... Goes ... ... Gets a Babysitter help,children cope with their own ...
... Progress in Women,s Cancer, Theme, Spotlights Four ... Cancers, CHICAGO, Feb. 11 The Society ... Meeting on Women,s Cancer March,9-12 at the Tampa ... will feature more than 350 scientific presentations,lectures, workshops, ...
Cached Medicine News:Health News:Charlotte IVF Experts Issue Urgent Call for Egg Donors, Eye New Recruiting Tools 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 3Health News:Blind Tibetan Teenagers Featured in Award-Winning Film, 'Blindsight,' Unite with Students from Junior Blind of America to Share Life Experiences 2Health News:Blind Tibetan Teenagers Featured in Award-Winning Film, 'Blindsight,' Unite with Students from Junior Blind of America to Share Life Experiences 3Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 2Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 3Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 3
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
... The BrachySource iodine-125 implant is a combination ... remarkable visibility that makes BrachySource I-125 implant ... You can be confident that every BrachySource ... seed management services which is required by ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: